Verve Therapeutics (NASDAQ:VERV) Trading 8.6% Higher - Time to Buy?

Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) shares were up 8.6% during trading on Thursday . The company traded as high as $6.01 and last traded at $5.96. Approximately 1,076,467 shares changed hands during mid-day trading, a decline of 17% from the average daily volume of 1,300,895 shares. The stock had previously closed at $5.49.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. HC Wainwright reduced their price objective on Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th.

Verve Therapeutics Price Performance

The company has a market capitalization of $516.43 million, a price-to-earnings ratio of -2.48 and a beta of 1.68. The company's 50-day moving average price is $5.81 and its two-hundred day moving average price is $5.74.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.11. The company had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm's revenue for the quarter was up 120.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.72) EPS. On average, equities research analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Verve Therapeutics

A number of large investors have recently bought and sold shares of VERV. GAMMA Investing LLC grew its stake in shares of Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after buying an additional 3,964 shares during the period. Creative Planning bought a new position in Verve Therapeutics in the third quarter worth approximately $50,000. PFG Investments LLC acquired a new stake in Verve Therapeutics in the third quarter valued at approximately $53,000. Erste Asset Management GmbH bought a new position in shares of Verve Therapeutics in the 3rd quarter worth $56,000. Finally, Daiwa Securities Group Inc. grew its position in Verve Therapeutics by 89.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company's stock valued at $59,000 after purchasing an additional 5,723 shares during the period. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.